New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM
− Sustained Benefit of Vutrisiran Across Mortality, Cardiovascular Events, Quality of Life and Cardiac Biomarkers Observed Through Up to 48 Months, Including 12... Read more.
Gold Reserve Provides Update on U.S. Government’s Statement of Interest Supporting Venezuelan Opposition Government in Litigation Regarding Validity of 2020 PDVSA Bonds
PEMBROKE, Bermuda–(BUSINESS WIRE)–Gold Reserve Ltd. (TSX.V: GRZ) (BSX: GRZ.BH) (OTCQX: GDRZF) (“Gold Reserve” or the “Company”) announces that... Read more.
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C
Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management.... Read more.
Daiichi Sankyo Announces the Development of a Fixed-Triple Combination Lipid-Lowering Tablet to Address Persistent Gaps in the Management of Elevated LDL-C
MUNICH, Germany–(BUSINESS WIRE)–Daiichi Sankyo Europe is pleased to announce the development of a fixed-triple oral combination lipid-lowering tablet... Read more.
Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension
– Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 – – In the Phase... Read more.
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
– Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 –... Read more.
Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial
Baxdrostat 2mg lowered systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) from baseline, and was generally well tolerated with no unanticipated safety... Read more.
FS Launches DCS-W Series Optical Circuit Switches to Power Next-Gen AI and HPC Networks
NEW CASTLE, Del.–(BUSINESS WIRE)–#AI–FS, a trusted global provider of ICT products and solutions, announced the launch of its independently developed... Read more.
Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction
Results from the Phase 3 VICTOR trial and a pooled analysis of the VICTOR and VICTORIA trials were presented today at the ESC Congress 2025 and simultaneously published... Read more.
$2 Billion Lower Amber Energy Bid Recommended by Special Master in CITGO Sale Process
PEMBROKE, Bermuda–(BUSINESS WIRE)–Gold Reserve Ltd. (TSX.V: GRZ) (BSX: GRZ.BH) (OTCQX: GDRZF) (“Gold Reserve” or the “Company”) announces that... Read more.